360 related articles for article (PubMed ID: 19279103)
21. A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.
Hessel A; Schwendinger M; Fritz D; Coulibaly S; Holzer GW; Sabarth N; Kistner O; Wodal W; Kerschbaum A; Savidis-Dacho H; Crowe BA; Kreil TR; Barrett PN; Falkner FG
PLoS One; 2010 Aug; 5(8):e12217. PubMed ID: 20808939
[TBL] [Abstract][Full Text] [Related]
22. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.
Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
Vaccine; 2009 Oct; 27(45):6296-9. PubMed ID: 19840663
[TBL] [Abstract][Full Text] [Related]
23. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
24. Monovalent H5 vaccine based on epitope-chimeric HA provides broad cross-clade protection against variant H5N1 viruses in mice.
He F; Prabakaran M; Rajesh Kumar S; Tan Y; Kwang J
Antiviral Res; 2014 May; 105():143-51. PubMed ID: 24637255
[TBL] [Abstract][Full Text] [Related]
25. Recombinant parainfluenza virus 5 expressing hemagglutinin of influenza A virus H5N1 protected mice against lethal highly pathogenic avian influenza virus H5N1 challenge.
Li Z; Mooney AJ; Gabbard JD; Gao X; Xu P; Place RJ; Hogan RJ; Tompkins SM; He B
J Virol; 2013 Jan; 87(1):354-62. PubMed ID: 23077314
[TBL] [Abstract][Full Text] [Related]
26. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.
Kreijtz JH; Suezer Y; van Amerongen G; de Mutsert G; Schnierle BS; Wood JM; Kuiken T; Fouchier RA; Lower J; Osterhaus AD; Sutter G; Rimmelzwaan GF
J Infect Dis; 2007 Jun; 195(11):1598-606. PubMed ID: 17471429
[TBL] [Abstract][Full Text] [Related]
27. MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses.
Hessel A; Savidis-Dacho H; Coulibaly S; Portsmouth D; Kreil TR; Crowe BA; Schwendinger MG; Pilz A; Barrett PN; Falkner FG; Schäfer B
PLoS One; 2014; 9(2):e88340. PubMed ID: 24523886
[TBL] [Abstract][Full Text] [Related]
28. Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus.
Kapczynski DR; Esaki M; Dorsey KM; Jiang H; Jackwood M; Moraes M; Gardin Y
Vaccine; 2015 Feb; 33(9):1197-205. PubMed ID: 25613723
[TBL] [Abstract][Full Text] [Related]
29. Construction of a recombinant duck enteritis virus (DEV) expressing hemagglutinin of H5N1 avian influenza virus based on an infectious clone of DEV vaccine strain and evaluation of its efficacy in ducks and chickens.
Wang J; Ge A; Xu M; Wang Z; Qiao Y; Gu Y; Liu C; Liu Y; Hou J
Virol J; 2015 Aug; 12():126. PubMed ID: 26263920
[TBL] [Abstract][Full Text] [Related]
30. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
[TBL] [Abstract][Full Text] [Related]
31. Sensitization with vaccinia virus encoding H5N1 hemagglutinin restores immune potential against H5N1 influenza virus.
Yasui F; Itoh Y; Ikejiri A; Kitabatake M; Sakaguchi N; Munekata K; Shichinohe S; Hayashi Y; Ishigaki H; Nakayama M; Sakoda Y; Kida H; Ogasawara K; Kohara M
Sci Rep; 2016 Nov; 6():37915. PubMed ID: 27892498
[TBL] [Abstract][Full Text] [Related]
32. A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice.
Zheng L; Wang F; Yang Z; Chen J; Chang H; Chen Z
BMC Infect Dis; 2009 Feb; 9():17. PubMed ID: 19216752
[TBL] [Abstract][Full Text] [Related]
33. Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin.
Alexander J; Ward S; Mendy J; Manayani DJ; Farness P; Avanzini JB; Guenther B; Garduno F; Jow L; Snarsky V; Ishioka G; Dong X; Vang L; Newman MJ; Mayall T
PLoS One; 2012; 7(2):e31177. PubMed ID: 22363572
[TBL] [Abstract][Full Text] [Related]
34. Safety, Immunogenicity, and Protective Efficacy of an H5N1 Chimeric Cold-Adapted Attenuated Virus Vaccine in a Mouse Model.
Sun W; Wang Z; Sun Y; Li D; Zhu M; Zhao M; Wang Y; Xu J; Kong Y; Li Y; Feng N; Wang T; Zhao Y; Yang S; Gao Y; Xia X
Viruses; 2021 Dec; 13(12):. PubMed ID: 34960689
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
[TBL] [Abstract][Full Text] [Related]
36. Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian influenza virus challenge.
Wang SH; Smith D; Cao Z; Chen J; Acosta H; Chichester JA; Yusibov V; Streatfield SJ; Fattom A; Baker JR
Vaccine; 2019 Mar; 37(12):1591-1600. PubMed ID: 30795941
[TBL] [Abstract][Full Text] [Related]
37. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.
Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
J Infect Dis; 2009 Feb; 199(3):405-13. PubMed ID: 19061423
[TBL] [Abstract][Full Text] [Related]
38. Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine.
Pandey A; Singh N; Vemula SV; Couëtil L; Katz JM; Donis R; Sambhara S; Mittal SK
PLoS One; 2012; 7(3):e33428. PubMed ID: 22432020
[TBL] [Abstract][Full Text] [Related]
39. Multiple-clade H5N1 influenza split vaccine elicits broad cross protection against lethal influenza virus challenge in mice by intranasal vaccination.
Yang P; Duan Y; Zhang P; Li Z; Wang C; Dong M; Tang C; Xing L; Gu H; Zhao Z; Liu X; Zhang S; Wang X
PLoS One; 2012; 7(1):e30252. PubMed ID: 22279575
[TBL] [Abstract][Full Text] [Related]
40. Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice.
Poon LL; Leung YH; Nicholls JM; Perera PY; Lichy JH; Yamamoto M; Waldmann TA; Peiris JS; Perera LP
J Immunol; 2009 Mar; 182(5):3063-71. PubMed ID: 19234203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
